Linker Information
General Information of This Linker
| Linker ID |
LIN00116
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Thioglycolic acid
|
|||||
| Structure |
|
|||||
| Formula |
C2H4O2S
|
|||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 92.12 | ||||
| Lipid-water partition coefficient (xlogp) | 0.1 | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | |||||
| Rotatable Bond Count (rotbonds) | 1 | |||||
| Chemble ID | ||||||
| PubChem CID | ||||||
| Canonical smiles |
C(C(=O)O)S
|
|||||
| InChI |
InChI=1S/C2H4O2S/c3-2(4)1-5/h5H,1H2,(H,3,4)
|
|||||
| InChIKey |
CWERGRDVMFNCDR-UHFFFAOYSA-N
|
|||||
| IUPAC Name |
2-sulfanylacetic acid
|
|||||
Each Peptide-drug Conjugate Related to This Linker
Full Information of The Activity Data of The PDC(s) Related to This Linker
SBI1301 [Preclinical]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Prostate cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
10%
|
|||
| Administration Time | 54 days | ||||
| Administration Dosage | 0.3 mg/kg | ||||
| Evaluation Method | Tumor volume detection | ||||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vivo Model | PC-3 mouse xenograft with prostate cancer | ||||
| Experiment 2 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Prostate cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
75%
|
|||
| Administration Time | 54 days | ||||
| Administration Dosage | 0.6 mg/kg | ||||
| Evaluation Method | Tumor volume detection | ||||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vivo Model | PC-3 mouse xenograft with prostate cancer | ||||
| Experiment 3 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Prostate cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
100%
|
|||
| Administration Time | 54 days | ||||
| Administration Dosage | 1.2 mg/kg | ||||
| Evaluation Method | Tumor volume detection | ||||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vivo Model | PC-3 mouse xenograft with prostate cancer | ||||
| Experiment 4 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Prostate cancer | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) |
100%
|
|||
| Administration Time | 54 days | ||||
| Administration Dosage | 2.4 mg/kg | ||||
| Evaluation Method | Tumor volume detection | ||||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vivo Model | PC-3 mouse xenograft with prostate cancer | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Pancreatic cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
2.3 nM
|
|||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cell | CVCL_0186 | ||
| Experiment 2 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Pancreatic cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
2.4 nM
|
|||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vitro Model | Prostate carcinoma | PC-3 cell | CVCL_0035 | ||
| Experiment 3 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Pancreatic cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
2.6 nM
|
|||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | MIA PaCa-2 cell | CVCL_0428 | ||
| Experiment 4 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Uterine corpus sarcoma | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.7 nM
|
|||
| Description |
In xenografted prostate cancer in mice, only 3 treatments over 12 days showed complete tumor regression. At the highest dose tested, there were no obvious symptoms of toxicity. After 60 days of observation, the tumor did not regrow.
|
||||
| In Vitro Model | Uterine corpus sarcoma | MES-SA cell | CVCL_1404 | ||